Edaravone Exerts Protective Effects on Mice Intestinal Injury without Interfering with the Anti-Tumor Effects of...

Area of Science:

• Radiation oncology
• Gastroenterology
• Pharmacology

Background:

• The radioprotective potential of edaravone and its impact on tumor response remain unclear.
• Radiation therapy often causes gastrointestinal side effects, necessitating protective strategies.

Purpose of the Study:

• To investigate the efficacy of edaravone as a radioprotective agent against intestinal injury.
• To determine if edaravone influences the efficacy of radiation therapy on tumors.

Main Methods:

• Mice received X-ray irradiation to induce intestinal mucositis and tumors.
• Edaravone was administered at various doses (15, 30, 100 mg/kg) before irradiation.
• Histological analysis and in vivo-in vitro colony formation assays assessed intestinal damage and tumor cell viability.

Main Results:

• Edaravone (100 mg/kg) significantly increased intestinal colony-forming ability post-irradiation.
• Reduced apoptotic cells in villi were observed with 100 mg/kg edaravone treatment.
• Edaravone did not exhibit radioprotective effects on squamous cell carcinoma VII tumors.

Conclusions:

• Edaravone at 100 mg/kg demonstrates radioprotective effects on the small intestine.
• Edaravone does not interfere with the antitumor effects of radiation therapy.
• Edaravone is a potential therapeutic agent for mitigating radiation-induced intestinal toxicity.